Interim results from an ongoing clinical trial show that patients with relapsed or refractory chronic lymphocytic leukemia treated with rituximab plus venetoclax have longer progression-free survival compared with patients treated with chemotherapy.
http://ift.tt/2qy3oc4
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου